右美托咪定靶控输注系统的建立与准确性评价

注册号:

Registration number:

ChiCTR2100045701 

最近更新日期:

Date of Last Refreshed on:

2021-12-07 02:42:13 

注册时间:

Date of Registration:

2021-04-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

右美托咪定靶控输注系统的建立与准确性评价

Public title:

Establishment and accuracy evaluation of dexmedetomidine target controlled infusion system

注册题目简写:

English Acronym:

研究课题的正式科学名称:

右美托咪定靶控输注系统的建立与准确性评价

Scientific title:

Establishment and accuracy evaluation of dexmedetomidine target controlled infusion system

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

黎治滔 

研究负责人:

黎治滔 

Applicant:

Li Zhitao 

Study leader:

Li Zhitao 

申请注册联系人电话:

Applicant telephone:

+86 15986636692

研究负责人电话:

Study leader's
telephone:

+86 15986636692

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lytow@qq.com

研究负责人电子邮件:

Study leader's E-mail:

lytow@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

深圳市福田区莲花路1120号

研究负责人通讯地址:

深圳市福田区莲花路1120号

Applicant address:

1120 Lianhua Road, Futian District, Shenzhen

Study leader's address:

1120 Lianhua Road, Futian District, Shenzhen

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学深圳医院

Applicant's institution:

Peking University Shenzhen Hospital

研究负责人所在单位:

北京大学深圳医院

Affiliation of the Leader:

Peking University Shenzhen Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021-013

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京大学深圳医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of Peking University Shenzhen Hospital Medical

伦理委员会批准日期:

Date of approved by ethic committee:

2021-04-20 00:00:00

伦理委员会联系人:

许卫卫

Contact Name of the ethic committee:

Xu Weiwei

伦理委员会联系地址:

深圳市福田区莲花路1120号

Contact Address of the ethic committee:

1120 Lianhua Road, Futian District, Shenzhen

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 755 83923333 6418

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学深圳医院

Primary sponsor:

Peking University Shenzhen Hospital

研究实施负责(组长)单位地址:

深圳市福田区莲花路1120号

Primary sponsor's address:

1120 Lianhua Road, Futian District, Shenzhen

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

深圳

市(区县):

Country:

China

Province:

Shenzhen

City:

单位(医院):

北京大学深圳医院

具体地址:

福田区莲花路1120号

Institution
hospital:

Peking University Shenzhen Hospital

Address:

1120 Lianhua Road, Futian District

经费或物资来源:

北京大学深圳医院临床研究项目资助

Source(s) of funding:

Supported by the Clinical Research Project of Peking University Shenzhen Hospital

研究疾病:

术中镇静  

Target disease:

Intraoperative sedation

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

本研究拟建立以中国人群为基础的右美托咪定靶控输注系统,并评价其临床应用准确性。  

Objectives of Study:

This study aims to establish a Chinese population-based target controlled infusion system of dexmedetomidine and evaluate its clinical application accuracy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.术前长期服用镇静镇痛剂患者;
2.心肺功能不全患者;
3.怀孕或哺乳期患者;
4.肥胖患者。

Exclusion criteria:

1. Patients who take sedative analgesics for a long time before surgery;
2. Patients with cardiopulmonary insufficiency;
3. Pregnant or lactating patients;
4. Obese patients.

研究实施时间:

Study execute time:

From 2021-05-01 00:00:00 To 2024-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-05-01 00:00:00 To 2024-01-01 00:00:00

干预措施:

Interventions:

组别:

组1

样本量:

10

Group:

Group 1

Sample size:

干预措施:

静脉恒速泵注右美托咪定

干预措施代码:

Intervention:

Intravenous infusion of dexmedetomidine at constant rate

Intervention code:

组别:

组2

样本量:

22

Group:

Group 2

Sample size:

干预措施:

靶控输注右美托咪定

干预措施代码:

Intervention:

Target controlled infusion of dexmedetomidine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

深圳 

市(区县):

 

Country:

China

Province:

Shenzhen

City:

单位(医院):

北京大学深圳医院 

单位级别:

三级甲等 

Institution
hospital:

Peking University Shenzhen Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

效应室转运速率常数(Ke0)

指标类型:

主要指标

Outcome:

Effect chamber transport rate constant(KeO)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

系统执行误差

指标类型:

主要指标

Outcome:

System execution error

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 55 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机对照试验

Randomization Procedure (please state who generates the random number sequence and by what method):

Non randomized controlled trial

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

开放

Blinding:

Open-label

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验结束后抹去患者私密信息后上传至本平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the experiment is finished, the patient's private information is erased and uploaded to the platform

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2021-04-23 04:09:30